Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) As Neoadjuvant Therapy For Pancreatic Adenocarcinoma

Study Overview

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib). The objective is to assess tolerability and the resection rate of patients with borderline resectable pancreatic adenocarcinoma who use this treatment.

The investigators propose treating 6-12 patients during the phase 1 portion and 40 patients in the phase 2 stage. Phase 1 Stage: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with escalating doses (400mg, or 600mg, or 800mg) of LDE-225. After completion of neoadjuvant therapy, the subjects will receive combined chemotherapy and radiation. Then subjects who are eligible for resection will go ahead with surgery. Following resection, subjects will complete two additional cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 in combination with LDE-225. Phase 2 Stage: In the Phase 2 stage the patients will be randomized to receive gemcitabine and nab-paclitaxel with or without the hedgehog inhibitor LDE225: 1. Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. 2. Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m on days 1, 8 and 15. After completion of neoadjuvant therapy, the subjects will receive combined chemotherapy and radiation. Then subjects who are eligible for resection will go ahead with surgery. Following resection, subjects will complete two additional cycles of the pre-surgical therapy. Several correlative laboratory studies will be conducted during the course of this study. They were designed around the goals of providing us with a better understanding of how the stroma-tumor interaction and the intra-tumoral drug levels of gemcitabine are affected with the use of LDE-225. Two additional biopsies are required to participate in this study.

Pancreatic Ductal Adenocarcinoma

DRUG: LDE225-600mg
DRUG: Gemcitabine
DRUG: nab-paclitaxel
DRUG: LDE225-400mg
DRUG: LDE225-800mg

J1130
NA_00047491 (OTHER Identifier) (OTHER: JHMIRB)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2011-07-19	Results First Submitted 2019-03-01	Last Update Submitted that met QC Criteria 2020-01-17
First Submitted that Met QC Criteria 2011-09-08	Results First Submitted that Met QC Criteria 2019-06-03	Last Update Posted (ACTUAL) 2020-01-22
First Posted (ACTUAL) 2011-09-12	Results First Posted 2019-06-25	Last Verified 2020-01

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Phase I-Gem,nab-paclitaxel,LDE225-600mg Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.	DRUG: LDE225-600mg Phase I: oral LDE225 (Sonidegib), 600mg daily. Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days. DRUG: Gemcitabine Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: nab-paclitaxel Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
ACTIVE_COMPARATOR: Phase II-Arm A:Gem,nab-paclitaxel,LDE225 Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.	DRUG: LDE225-600mg Phase I: oral LDE225 (Sonidegib), 600mg daily. Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days. DRUG: Gemcitabine Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: nab-paclitaxel Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: LDE225-400mg Phase I: oral LDE225 (Sonidegib), 400mg daily. DRUG: LDE225-800mg Phase I: oral LDE225 (Sonidegib), 800mg daily.
ACTIVE_COMPARATOR: Phase II-Arm B:Gem,nab-paclitaxel Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.	DRUG: Gemcitabine Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: nab-paclitaxel Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
EXPERIMENTAL: Phase I-Gem,nab-paclitaxel,LDE225-400mg Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.	DRUG: Gemcitabine Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: nab-paclitaxel Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: LDE225-400mg Phase I: oral LDE225 (Sonidegib), 400mg daily.
EXPERIMENTAL: Phase I-Gem,nab-paclitaxel,LDE225-800mg Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.	DRUG: Gemcitabine Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: nab-paclitaxel Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days. DRUG: LDE225-800mg Phase I: oral LDE225 (Sonidegib), 800mg daily.

Primary Outcome Measures	Measure Description	Time Frame
Phase I - Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy as Measured by Number of Participants Who Tolerated the Maximal Dose of LDE-225	Number of participants who tolerated the maximal dose of LDE-225 in combination with gemcitabine, nab-paclitaxel as neoadjuvant therapy in patients with borderline resectable pancreatic adenocarcinoma (PDA).	5 years
Phase II - Resection Rate of Two Preoperative Chemotherapy Regimens in Patients With Borderline Resectable PDA	Number of participants with borderline resectable pancreatic adenocarcinoma (PDA) who undergo resection after therapy	5 years

Secondary Outcome Measures	Measure Description	Time Frame
Overall Survival	Number of months alive from cycle 1, Day 1 until 5 years post-intervention or death, whichever comes first.	5 years
Overall Tumor Response as Determined by Number of Participants With Complete or Partial Response	Number of participants who experienced complete response (CR) or partial response (PR), as defined by RECIST v1.0; where CR is a disappearance of all target lesions and PR is ≥30% reduction of target lesions.	5 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Histologically or cytologically confirmed adenocarcinoma of the pancreas.
Must have borderline resectable pancreatic adenocarcinoma
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension
No previous radiotherapy, surgery, chemotherapy or investigational drug therapy.
Age >18 years
Life expectancy of greater than 1 month.
ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1
Adequate organ and marrow function
Asymptomatic for jaundice and ascites. Pain symptoms should be stable.
Negative serum pregnancy test
Sexually active males should agree to use a barrier form of contraception, even if they have had a vasectomy, during the study and for 6 months after stopping LDE225. Males should not donate sperm during treatment, and for up to six months after last dose. Sexually active females of child bearing potential agree to using highly effective contraception during study and for 20 months after final dose of LDE225.
Agree not to donate blood products for 12 months after stopping LDE225.
Willing to have two biopsies while on treatment for correlative studies.

Patients who have had previous radiotherapy, surgical resection, chemotherapy or investigational drug therapy for pancreatic adenocarcinoma.
Patient has known metastatic disease.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to LDE225 or other agents used in the study.
Patients taking medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®)
Uncontrolled illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure not controlled with medication, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women are excluded
Patient has undergone a major surgery, other than diagnostic surgery within four weeks prior to starting treatment on this study.
Patients who are receiving treatment with medications known to be moderate and strong inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with LDE225.
Patients with neuromuscular disorders.
Patients with impaired cardiac function.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Novartis Pharmaceuticals
The Skip Viragh Foundation

Investigators

PRINCIPAL_INVESTIGATOR: Ana De Jesus-Acosta, MD, Sidney Kimmel Comprehensive Cancer Center JHMI

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record